Fewer than 10 people, under a year old: Anthropic reportedly paid $400 million for this biotech AI startup; what does it do?

Anthropic acquired New York-based biotech AI startup Coefficient Bio in April 2026. According to The Information, it was acquired for $400 million. The deal came as Anthropic continued its push into healthcare and life sciences. In its October announcement, the company mentioned Claude for Life Sciences, which is a tool that aims to help scientific researchers make discoveries. But, the most interesting part of the story is not the deal or the numbers. It is that Coefficient Bio’s team had less than 10 employees, and was set to join Anthropic’s healthcare and life sciences group.

All about Coefficient Bio

Samuel Stanton and Nathan C. Frey are the founders of Coefficient Bio. The startup was launched just eight months before the deal, according to reports. They both had previously worked in computational drug discovery at Genentech’s Prescient Design.

Coefficient Bio used artificial intelligence in order to help make drug discovery and other forms of biological research more efficient.

All about the deal

Anthropic’s Claude for Life Sciences was launched in October 2025. As part of the deal, the New York-based startup’s team joined Anthropic’s healthcare initiatives. This showed Anthropic’s big push into life sciences and drug discovery.

ALSO READ: This drug-development startup raised about $20 million; now its team builds OpenAI’s life-sciences AI; here’s what you need to know

Anthropic has some growing ambitions, and this deal aligns with them. According to reports, it is due to a major focus in the fields of healthcare and scientific research.
The company is known for its Claude family of AI models, and had expanded use cases beyond general-purpose AI to domain-specific applications. In early 2026, it also introduced Claude for Healthcare. The aim was to support workflows across research, clinical trials, and regulatory operations.

The deal shows Anthropic’s vision and it matters as it signals where the company is taking Claude in the next few months. According to reports, the expertise of Coefficient Bio in drug discovery and computational biology could help and strengthen Anthropic’s capabilities in this area.